Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
Inspire Medical Systems (INSP) announced that Chief Financial Officer Richard J. Buchholz has notified the company he will step down to pursue other professional opportunities. Mr. Buchholz and the company entered a Transition and Separation Agreement under which his resignation will be effective on the earlier of December 31, 2025 or the date a permanent successor CFO commences employment. He will remain principal financial and accounting officer through that date and then serve as a financial advisor through February 28, 2026 while receiving base salary and benefits.
The agreement provides for a cash payment equal to nine months of his 2025 annual base salary and up to nine months of COBRA coverage. The company has engaged a leading executive search firm to recruit a new CFO. The filing discloses customary confidentiality, non-disparagement and release provisions and incorporates the full separation agreement as Exhibit 10.1 and a press release as Exhibit 99.1.
Inspire Medical Systems CFO Richard Buchholz reported multiple acquisitions of company stock on 08/19/2025. He exercised employee stock options and purchased shares, increasing his direct holdings. The Form 4 shows exercises of options with strike prices of $71 (17,849 shares) and $42.15 (7,159 shares), plus recognition of shares withheld for tax obligations (2,649; 2,455; 276) and 113 shares from the 2018 Employee Stock Purchase Plan. After the transactions, his reported direct common stock holdings range across entries (for example, 61,247 and 58,598 shares). Certain family members are reported as indirect holders (each 1,475 shares).
Inspire Medical Systems disclosed that its Board has authorized the repurchase of up to $200.0 million of the company’s outstanding common stock. The filing indicates the board approved a buyback authorization but does not include details on timing, methods, or the pace of repurchases.
The filing also furnishes the company press release as Exhibit 99.1 and includes Inline XBRL cover page tags. No financial results, program specifics, or additional transaction terms are provided within this report.